Armonica Technologies is an early stage medtech company developing its proprietary long-read sequencing platform for precision medicine applications. Armonica’s approach employs nanochannels to deliver single nucleic acid molecules through nanopores for optical readout by Raman spectroscopy, enabling direct reading of characteristic nucleotide and epigenetic signatures.
A fundamental issue for pore-based sequencing techniques is the speed of nucleic acid translocation. Our “tortuous nanopore” platform provides an elegant, inexpensive and manufacturable solution to this challenge.
Armonica Technologies, Inc., a biotechnology company developing a novel DNA sequencing system based on single molecule spectroscopy, announced that the company has been awarded a follow-on Phase II SBIR grant [...]